The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V09 | Diagnostic radiopharmaceuticals | |
| 3 | V09A | Central nervous system | |
| 4 | V09AX | Other central nervous system diagnostic radiopharmaceuticals | |
| 5 | V09AX06 |
| Active Ingredient | Description | |
|---|---|---|
| Florbetaben ¹⁸F |
Florbetaben ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| NEURACEQ Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
